Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...

A whopping 85% of men experience significantly thinning hair by age 50, and two-thirds experience noticeable hair loss by age ...

Hims & Hers executives struck a confident tone about the company's growth prospects on Monday as it launches new specialties and expands rapidly into international markets. | Investors are concerned ...

Novo Nordisk vowed to take legal action against Hims & Hers after the telehealth platform launched a cheaper, copycat version of the pharmaceutical giant’s Wegovy GLP-1 weight loss pill. In a Feb. 5 ...

By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky ...

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

By Stine Jacobsen and Maggie Fick COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U.S. telehealth firm launched, then cancelled, a $49 ...

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a ...